I'd like to discuss the similarities between polymyalgia rheumatica and palindromic rheumatism. And in doing that, highlight how these similarities help us understand the relationship between polymyalgia rheumatica and rheumatoid arthritis. Perhaps not everybody watching this will be very familiar with palindromic rheumatism. It is considered uncommon, but every rheumatologist sees it in their practice.
All News
EULAR has published updated recommendations for the management of systemic lupus erythematosus (SLE) based on new evidence and expert opinion - formulationg five overarching principles and 13 recommendations.
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com.
In this Tuesday Night Rheumatology webinar, the panel discussed the use of corticosteroids in patients with polymyalgia rheumatica. Panelists: Drs. Lindsay Lally, Richard Conway and Max Yates. Moderated by Dr. David Liew.
Dr. Jack Cush reviews the big PMR reports from this week along with other journal reports from RheumNow.com.
NEJM reported today that polymyalgia rheumatica (PMR) patients who fail to respond to standard doses of prednisone therapy, were significantly better when given the IL-6 inhibitor sarilumab (than placebo).
Panelists Dr. Claire Owen, Stephen Paget, Anisha Dua and Jack Cush discuss diagnosis and monitoring in PMR during this week's Tuesday Night Rheumatology.
What’s your next best approach to the rheumatoid arthritis (RA) patient who has failed several DMARDs and biologics? In such cases you have to either reconsider the diagnosis (especially if seronegative) or reach into your bag of tricks.
Dr. Jack Cush is joined by Dr. Michael Weinblatt as they discuss this weeks news and journal reports, including difficult RA, HLA typing and abatacept responses and new regulatory decisions.
This Tuesday Night Rheumatology was an hour long panel discussion featuring Drs. Jack Cush, Vivian Bykerk, Glen Hazelwood and Martin J. Bergman.
The Panel discussed Rheumatologists views on Early RA referral and intake, initial treatment preferences and views on diagnosing and treating pre-clinical RA.
The US Food and Drug Administration (FDA) has approved canakinumab (Ilaris) for the treatment of gout flares in adults who cannot be treated with NSAIDs, colchicine, or repeated courses of corticosteroids. The drug is also indicated for people who could not tolerate or had an inadequate response to NSAIDs or colchicine.
The American College of Rheumatology (ACR) and EULAR have combined efforts to establish an international multidisciplinary Steering Committee to develop classification criteria for the new antiphospholipid syndrome (APS) to be applied in observational studies and clinical trials.
A nested case–control study from the Danish Nationwide Registries finds an increased risk of cardiovascular (CV) disease in the months preceding diagnosis of ANCA-associated vasculitis (AAV).
A pooled analysis of 5 randomized controlled trials (RCTs) shows that the effects of 2 years of low-dose glucocorticoid (GC) treatment in rheumatoid arthritis (RA) can significantly increase increase body weight, but not blood pressure.
Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology. This week:
The COLCHICORT trial in patients with acute calcium pyrophosphate crystal arthritis (CPPD) demonstrated equivalent efficacy for both colchicine and prednisone, yet different safety signals were seen.
